TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02127242

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ureteroscopic air-pressure ballistic lithotripsy
Description: In case of large, hard or impacted stones ureteroscopic air-pressure ballistic lithotripter is used for fragmentation. The probe of the lithotripter target towards the stone and then fragmented.
Study: NCT00596622

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lithium
Description: Dosing will start as one 300-mg capsule per day and will be titrated up to four 300-mg capsules per day for a total of 8 weeks of treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lithium
Description: Dosing will start as one 300-mg capsule per day and will be titrated up to four 300-mg capsules per day for a total of 8 weeks of treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lithium
Description: Dosing will start as one 300-mg capsule per day and will be titrated up to four 300-mg capsules per day for a total of 8 weeks of treatment.
Study: NCT03181139

Intervention type: OTHER
Intervention: ERAS pathway for Total Mastectomy
Description: Enhanced Recovery after Surgery (ERAS) pathway for Total Mastectomy
Study: NCT03422536

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ficlatuzumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ficlatuzumab
Description: Given IV
Study: NCT01694108

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCG-vaccine (SSI)
Study: NCT03976999

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biological collection
Description: * Blood samples collected at different times : Before treatment (T1) , after chemotherapy (T2), after interval surgery (T3) and after cancer reccurence (T4)~* Tissue samples (tumor tissue and healthy tissue) collected during the surgery
Study: NCT03149029

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab is a type of antibody that inhibits the cancer cell growth

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab is a type of antibody that inhibits the cancer cell growth

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabrafenib
Description: Dabrafenib is also a cell inhibitor and works by stopping the cancer cell from duplicating

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Trametinib is a cell inhibitor that binds to the cancer cells to inhibit the cancer cells' signals to decrease cell growth

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Trametinib is a cell inhibitor that binds to the cancer cells to inhibit the cancer cells' signals to decrease cell growth
Study: NCT04093986

Intervention type: OTHER
Intervention: Chart Review
Description: Medical records or data available from previous clinical care prior to June 20, 2019 about pregnancy and breastfeeding outcomes, both for babies with hydroxyurea exposure and other babies by these same women.

Intervention type: OTHER
Intervention: Chart Review
Description: Medical records or data available from previous clinical care prior to June 20, 2019 about pregnancy and breastfeeding outcomes, both for babies with hydroxyurea exposure and other babies by these same women.

Intervention type: OTHER
Intervention: Survey
Description: Women who choose to participate directly and provide information in survey format will receive a brief survey and the option to upload their medical records (if available) into Cincinnati Children's maintained REDCap database.
Study: NCT01331928

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine (Xeloda, Roche), Oxaliplatin (Sanofi-Aventis), Docetaxel (Sanofi-Aventis)
Description: capecitabine orally 1000 mg/m2 twice daily, day1 to day 10, every 2 weeks plus oxaliplatin 85mg/m2 (2hrs IV infusion)on day1, every 2 weeks for 6 cycles, then shift to docetaxel 30 mg/m2(over 30-minute intravenous infusion) on day 1 and day 8 plus oral capecitabine 825 mg/m2 twice daily on day 1 to 14, every 3 weeks for 4 cycles.
Study: NCT04422054

Intervention type: PROCEDURE
Intervention: Open Surgery
Description: We will retrospectively review patients with abdominal aortic aneurysms that underwent open surgical repair.

Intervention type: PROCEDURE
Intervention: Endovascular Surgery
Description: We will retrospectively review patients with abdominal aortic aneurysms that underwent endovascular repair.
Study: NCT01091818

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexmedetomidine
Description: Dexemedethomidine is given as major sedative drug

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: Midazolam is given as major sedative drug
Study: NCT01207349

Intervention type: BEHAVIORAL
Intervention: Secondary prevention intervention trial
Description: Close follow-up by nurses, exercise physiologist and dieteticians
Study: NCT04087707

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Step 1: TS-142
Description: Non-elderly participants will receive 20 mg of TS-142 once daily for 7 consective days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Step 2: TS-142
Description: Elderly participants will receive 20 mg of TS-142 once daily for 7 consective days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Step 2: TS-142
Description: Elderly participants will receive 20 mg of TS-142 once daily for 7 consective days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Step 2: Placebo
Description: Elderly participants will receive placebo once daily for 7 consective days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Step 2: Placebo
Description: Elderly participants will receive placebo once daily for 7 consective days
Study: NCT03006276

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DFN-15 Active

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: DFN-15 Placebo
Study: NCT02490111

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWJ1319

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWJ1319

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04306003

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ERAS pathway
Description: See ERAS pathway arm description.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Perioperative Care
Description: See control arm description.
Study: NCT02715089

Intervention type: GENETIC
Intervention: Precise treatment
Description: During screening stage, all patients should accept next-generation sequencing (NGS) test.
Study: NCT01968629

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eovist
Study: NCT02303470

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Vigorous Exercise
Description: High-intensity interval training alternates 30 seconds of vigorous exercise with 30 seconds of low-intensity recovery for a total of 15 minutes.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Moderate Exercise
Study: NCT02948998

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spironolactone
Description: The participants in this arm will be prescribed to take 20mg spironolactone orally and daily. Serum potassium concentration and creatinine and blood pressure will be monitored regularly to make the participants safe.
Study: NCT02254694

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: high heeled shoes
Description: see detailed study description
Study: NCT03033290

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bu-Zhong-Yi-Qi-Tang
Description: Qi-tonifying regimen of traditional Chinese herbal medicine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo control
Study: NCT00665002

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: WT-1
Description: Immune responses were to be evaluated at weeks 6 and 12 via delayed-type hypersensitivity, CD4 T cell proliferation, CD4 and CD8 T cell interferon release, as well as by bone marrow cytogenetics including polymerase chain reaction (PCR) to look for molecular evidence of disease. Patients who had an immunologic response and had not had disease progression could continue with up to 6 more vaccinations administered approximately every month. In that case, patients were to be reevaluated with bone marrows/immunologic studies after the 9th and 12th vaccination. In addition, patients would undergo evaluations for residual disease including immunohistochemistry and/or quantitative polymerase chain reaction (RQ-PCR) for WT-1 expression (on selected patients), and multiparameter flow cytometry (AML/ MDS).
Study: NCT01207349

Intervention type: BEHAVIORAL
Intervention: standard follow up
Study: NCT01075503

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: brachial plexus block
Description: 0.5% Ropivacaine 40ml
Study: NCT00665002

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montanide
Description: The WT-1 vaccine is given with another substance, called Montanide, which clumps the WT-1 vaccine and thereby improves the immune response.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sargramostim (GM-CSF)
Description: GM-CSF was administered at a dose 70 mcg (140ul) as a subcutaneous injection at the site of vaccination on day -2 and day 0.
Study: NCT01652027

Intervention type: DRUG
Intervention: FVIII concentrate
Description: usual treatment as directed by treating physician
Study: NCT03343990

Intervention type: PROCEDURE
Intervention: Interlocking multi-twisted wires in sternal closure
Description: One of many ways in cloure of sternal give more stabilization. At least 6 wires have to be passed. The wirs should run around the sternum in the intercostals spaces except in the manubrium where it has to be passed through the bone . Adjacent wires on the surgeon's side are wrapped around each other. The wires on the surgeon's side are then pulled towards the assistant so that the sternum is re-approximated. Alternatively the surgeon can also pull the wires at the assistant's side towards himself or herself approximating the sternum. Adjacent wires on the assistant's side are then wrapped around each other. The wrapped wires on both sides are then wrapped around each other The wrapped wires are then twisted around with a twister, closing the sternum tightly and the ends of the are burried

Intervention type: PROCEDURE
Intervention: Interlocking multi-twisted wires in sternal closure
Description: One of many ways in cloure of sternal give more stabilization. At least 6 wires have to be passed. The wirs should run around the sternum in the intercostals spaces except in the manubrium where it has to be passed through the bone . Adjacent wires on the surgeon's side are wrapped around each other. The wires on the surgeon's side are then pulled towards the assistant so that the sternum is re-approximated. Alternatively the surgeon can also pull the wires at the assistant's side towards himself or herself approximating the sternum. Adjacent wires on the assistant's side are then wrapped around each other. The wrapped wires on both sides are then wrapped around each other The wrapped wires are then twisted around with a twister, closing the sternum tightly and the ends of the are burried

Intervention type: PROCEDURE
Intervention: Eight Figure techniqe in sternal closure
Description: The figure-eight closure is described as faster, simpler, and more reliable than its trans-sternal counterpart; with only oblique forces sutures are less likely to loosen or fracture the sternum. The advantage of figure-eight closure is that it allows oblique and horizontal angle of shearing forces instead of direct perpendicular forces. Thus these wires are less likely to loosen or fracture

Intervention type: PROCEDURE
Intervention: Eight Figure techniqe in sternal closure
Description: The figure-eight closure is described as faster, simpler, and more reliable than its trans-sternal counterpart; with only oblique forces sutures are less likely to loosen or fracture the sternum. The advantage of figure-eight closure is that it allows oblique and horizontal angle of shearing forces instead of direct perpendicular forces. Thus these wires are less likely to loosen or fracture
Study: NCT01464073

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LIPOXmax
Description: Arm 1: LIPOXmax arm. Subjects will perform a physical activity 4x1 hour per week at the optimal intensity for fat oxidation (LIPOXmax) measured by indirect calorimeter.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 60% VO2peak
Description: Arm 2: physical activity standard arm (60% of VO2max measured by cardio respiratory exercise test). Subjects will realize 4 sessions per week and duration of sessions will be adjusted so that arms 1 and 2 have the same total energy expenditure by session.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Good Medical Practices
Description: Arm 3: The subjects initially receive the recommendations of good medical practice for physical activity (achieving at least 30min per day of moderate exercise).

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: supplementation in fruits and vegetables
Description: all groups will be supplemented in fruits and vegetables (5 per day) during all the study

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: supplementation in fruits and vegetables
Description: all groups will be supplemented in fruits and vegetables (5 per day) during all the study

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: supplementation in fruits and vegetables
Description: all groups will be supplemented in fruits and vegetables (5 per day) during all the study
Study: NCT01075503

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: brachial plexus block
Description: 0.5% Ropivacaine 40ml

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: brachial plexus block
Description: 0.5% Ropivacaine 40ml
Study: NCT04518865

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Herbst appliance
Description: The bottom line of the study is to investigate the changes after Herbst appliance treatment and relate it to the pubertal status of the skeletal class II patients using CBCT.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Herbst appliance
Description: The bottom line of the study is to investigate the changes after Herbst appliance treatment and relate it to the pubertal status of the skeletal class II patients using CBCT.
Study: NCT00211926

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: S. aureus Type 5 & 8 Capsular Polysaccharide Conjugate
Description: single dose of vaccine containing 100 mcg of each serotype conjugate

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: single dose of placebo
Study: NCT03867656

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GLP-2
Description: GLP-2 injection

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GIP
Description: GIP injection

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo injection
Study: NCT01641848

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: INBONE™ Total Ankle Prosthesis with Long Talar Stem
Description: INBONE™ Total Ankle Prosthesis with Long Talar Stem when used with a Calcaneal Stem
Study: NCT03104712

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Spaghetti + Tomato Sauce
Description: 50g available carbohydrate

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rice + Tomato Sauce
Description: 50g available carbohydrate
Study: NCT03194438

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Urban Zen Integrative Therapy (UZIT)
Description: Multi-modal components integrative therapy program (UZIT) that includes essential oil, gentle body movement, body-awareness meditation, and Reiki.
Study: NCT04319887

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Evoke Spinal Cord Stimulation (SCS) System
Description: A spinal cord stimulation system that measures and records evoked compound action potentials (ECAPs) and automatically adjusts the stimulation current to maintain a consistent ECAP amplitude
Study: NCT02707796

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hemicolectomy
Study: NCT00958737

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX regimen
Description: 6 or 12 treatments of FOLFOX (FOLFOX4 or modified FOLFOX6 (mFOLFOX6))

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX regimen
Description: 6 or 12 treatments of FOLFOX (FOLFOX4 or modified FOLFOX6 (mFOLFOX6))

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAPOX
Description: 4 or 8 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAPOX
Description: 4 or 8 cycles
Study: NCT00708734

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: functional exercise training
Description: twice weekly group sessions for 5 weeks
Study: NCT04070495

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KW-6356
Description: A single oral dose will be administered at Day 1 and 15

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KW-6356
Description: A single oral dose will be administered at Day 1 and 15

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clarithromycin
Description: 400mg, oral tablet (2 x 200mg), twice daily (BID), Day 8-28

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampicin
Description: 600mg, oral tablet (4 x 150mg), once daily (QD), Day 8-21
Study: NCT01252524

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet po TID before each meal with 8 oz of water for 6 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium polycarbophil
Description: calcium polycarbophil 625 mg po TID before each meal with 8 oz water for 6 months
Study: NCT02942654

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY900014
Description: Administered subcutaneously (SC)
Study: NCT03104712

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Spaghetti + Pesto
Description: 50g available carbohydrate

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rice + Pesto
Description: 50g available carbohydrate
Study: NCT04574570

Intervention type: DEVICE
Group type: OTHER
Intervention: High Tibial Osteotomy
Description: Personalised High Tibial Osteotomy (HTO) using a patient-specific fixation plate (TOKA®)
Study: NCT00098423

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tanespimycin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Given IV
Study: NCT03338426

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fimasartan 120mg
Description: Fimasartan 120mg will be administrated once daily for 8 weeks treatment period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fimasartan 120mg
Description: Fimasartan 120mg will be administrated once daily for 8 weeks treatment period

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin 40mg
Description: Atorvastatin 40mg will be administrated once daily for 8 weeks treatment period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin 40mg
Description: Atorvastatin 40mg will be administrated once daily for 8 weeks treatment period

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo for Fimasartan 120mg
Description: Placebo for Fimasartan 120mg will be administrated once daily for 8 weeks treatment period
Study: NCT02942654

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Lispro
Description: Administered SC
Study: NCT02334397

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Total Control Program
Description: Women will be enrolled in Total Control, which is a fitness and education program.
Study: NCT03338426

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo for Atorvastatin 40mg
Description: Placebo for Atorvastatin 40mg will be administrated once daily for 8 weeks treatment period
Study: NCT00371254

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Tablets, Oral, 100 mg, twice daily as long as the patient benefits (avg \<6 months)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Tablets, Oral, 70 mg, twice daily as long as the patient benefits (avg \<6 months)
Study: NCT04409743

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Remote Cognitive Behavioral Therapy for Insomnia
Description: Participants will meet with a psychologist through telehealth once a week for four weeks to complete a brief CBT-I intervention. Cognitive Behavioral Therapy for Insomnia consists of a cognitive therapy and a behavioral therapy. The cognitive therapy is designed to identify incorrect ideas about sleep, challenge their validity, and replace them with correct information. This therapy tries to reduce worry, anxiety, and fear that one won't sleep by providing accurate information about sleep. The behavioral therapy increases sleep quality by limiting excessive time spent in bed to increase homeostatic sleep drive and sleep consolidation.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Remote Cognitive Behavioral Therapy for Insomnia
Description: Participants will meet with a psychologist through telehealth once a week for four weeks to complete a brief CBT-I intervention. Cognitive Behavioral Therapy for Insomnia consists of a cognitive therapy and a behavioral therapy. The cognitive therapy is designed to identify incorrect ideas about sleep, challenge their validity, and replace them with correct information. This therapy tries to reduce worry, anxiety, and fear that one won't sleep by providing accurate information about sleep. The behavioral therapy increases sleep quality by limiting excessive time spent in bed to increase homeostatic sleep drive and sleep consolidation.
Study: NCT01990495

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise training
Description: Subjects will participate in a center-based and home exercise training program for 3 months.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: This group will serve as control subjects. They will receive only usual clinical care.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: This group will serve as control subjects. They will receive only usual clinical care.
Study: NCT04109729

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab 480mg IV every 4 weeks for up to 2 years~• Radium-223 55 kBq/kg IV q4 weeks for 6 cycles total
Study: NCT02808416

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Personalized cellular vaccine
Description: Cancer patients with brain metastases will undergo tumor resection or biopsy, and receive tumor antigen mRNA pulsed cellular vaccines.~Other Names:~• Tumor antigen pulsed DC and PBMC, autologous tumor vaccine